The diagnostic accuracy of O-(2-18F-fluoroethyl)-L-tyrosine parameters for the differentiation of brain tumour progression from treatment-related changes. Issue 3 (March 2022)
- Record Type:
- Journal Article
- Title:
- The diagnostic accuracy of O-(2-18F-fluoroethyl)-L-tyrosine parameters for the differentiation of brain tumour progression from treatment-related changes. Issue 3 (March 2022)
- Main Title:
- The diagnostic accuracy of O-(2-18F-fluoroethyl)-L-tyrosine parameters for the differentiation of brain tumour progression from treatment-related changes
- Authors:
- Diao, Wei
Su, Dunyan
Cao, Yuan
Jia, Zhiyun - Abstract:
- Abstract : Background: 18 F-fluoro-ethyl-tyrosine ( 18 F-FET) is recommended to distinguish brain tumours post-therapeutic true progression (including recurrent and metastatic brain tumours) and treatment-related change (TRC). However, many parameters of 18 F-FET can be used for this differential diagnosis. Our purpose was to investigate the diagnostic accuracy of various 18 F-FET parameters to differentiate true progression from TRC. Methods: We performed a literature search using the following databases: the PubMed, Embase and Web of Science databases up to 29 November 2020. We included studies that reported the diagnostic test results of 18 F-FET to distinguish true progression from TRC. The Quality Assessment of Diagnostic Accuracy Studies-2 tool was used to evaluate the quality of the included studies. The diagnostic accuracy of various parameters was pooled using a random-effects model. Results: We included 17 eligible studies (nine parameters). For static parameters of 18 F-FET, the maximum and mean tumour-to-brain ratios (TBRmax and TBRmean ) showed similar pooled sensitivities of 82% [95% confidence interval (CI), 80–85%) and 82% (95% CI, 78–85%), respectively. Among the three kinetic parameters (slope, time to peak and kinetic pattern), the kinetic pattern presented the optimal diagnostic value with a pooled sensitivity of 81% (95% CI, 75–86%). When combining the static and kinetic parameters, the diagnostic performance of 18 F-FET was significantly improved, withAbstract : Background: 18 F-fluoro-ethyl-tyrosine ( 18 F-FET) is recommended to distinguish brain tumours post-therapeutic true progression (including recurrent and metastatic brain tumours) and treatment-related change (TRC). However, many parameters of 18 F-FET can be used for this differential diagnosis. Our purpose was to investigate the diagnostic accuracy of various 18 F-FET parameters to differentiate true progression from TRC. Methods: We performed a literature search using the following databases: the PubMed, Embase and Web of Science databases up to 29 November 2020. We included studies that reported the diagnostic test results of 18 F-FET to distinguish true progression from TRC. The Quality Assessment of Diagnostic Accuracy Studies-2 tool was used to evaluate the quality of the included studies. The diagnostic accuracy of various parameters was pooled using a random-effects model. Results: We included 17 eligible studies (nine parameters). For static parameters of 18 F-FET, the maximum and mean tumour-to-brain ratios (TBRmax and TBRmean ) showed similar pooled sensitivities of 82% [95% confidence interval (CI), 80–85%) and 82% (95% CI, 78–85%), respectively. Among the three kinetic parameters (slope, time to peak and kinetic pattern), the kinetic pattern presented the optimal diagnostic value with a pooled sensitivity of 81% (95% CI, 75–86%). When combining the static and kinetic parameters, the diagnostic performance of 18 F-FET was significantly improved, with a pooled sensitivity of 90% (95% CI, 84–94%) in the combination of TBR and kinetic patterns. Conclusions: 18 F-FET static parameters alone showed a comparably high sensitivity in the differentiation between brain tumour true progression and TRC. Combining static and kinetic parameters provided improved diagnostic performance. Abstract : Supplemental Digital Content is available in the text. … (more)
- Is Part Of:
- Nuclear medicine communications. Volume 43:Issue 3(2022)
- Journal:
- Nuclear medicine communications
- Issue:
- Volume 43:Issue 3(2022)
- Issue Display:
- Volume 43, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 43
- Issue:
- 3
- Issue Sort Value:
- 2022-0043-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-03
- Subjects:
- 18F-fluoro-ethyl-tyrosine -- brain tumour -- diagnostic accuracy -- meta-analysis -- PET -- pseudoprogression
Nuclear medicine -- Periodicals
616.07575 - Journal URLs:
- http://journals.lww.com/nuclearmedicinecomm/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
http://www.lww.com/Product/0143-3636 ↗ - DOI:
- 10.1097/MNM.0000000000001524 ↗
- Languages:
- English
- ISSNs:
- 0143-3636
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6180.923000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26800.xml